Get all premium features to the best stock analysis tool

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology.

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline. SO WHAT: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) ("Corcept" or the "Company"), if they purchased or otherwise acquired the Company's shares between October 31, 2024 and December 30, 2025, inclusive (the "Class Period").

It earned FDA approval for its cancer drug, Lifyorli. This earned a recommendation upgrade from an analyst.

SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026. The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.

New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).